Results

Total Results: 1,147 records

Showing results for "event".

181. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/LPaUxRbrTshfsYVVTzenEQ
     April 26, 2022 - It is important to note that increasing age heavily influ- ences the ACC/AHA estimated 10-year CVD event … have initiated aspirin use, the net benefits continue to accrue over time in the absence of a bleeding event

182. ahrq12a_Summary_HBP.qxd (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/BXkaHRFGjwUCoyANeMSuTz
     January 01, 2010 - numbers needed to treat (NNT) over 5 years ranged from 200 to 400 to prevent 1 congestive heart failure event … ranged from approximately 900 to prevent 1 stroke to 10,000 to prevent 1 case of coronary heart disease event … The number needed to treat over 5 years to prevent 1 cardiovascular event was 18 (95% CI 17 to 19) in

183. Draft Recommendation: Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/tobacco-smoking-cessation-in-adults-including-pregnant-women-interventions
     June 02, 2020 - in progress Draft Recommendation Statement Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons June 02, 2020 Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality…

184. Archived: Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions-september-2015
     September 21, 2015 - compared with those receiving placebo (RR, 1.36 [CI, 1.03 to 1.81]), but the type of serious adverse event

185. Screening for Glaucoma in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/mf27sR5jgcrqcaY9t8d8Jt
     April 04, 2022 - RR, 2.40 [95% CI, 0.71-19.32]; I2 = 0%) (eFigure 8 in the Supplement),21,37,41,90,106 or any adverse event … , 0.59-4.03]; I2 = 82%).41,76,77 However, estimates were imprecise and the estimate for any adverse event … The LiGHT trial found no differences between SLT and medical therapy in likelihood of any adverse event … placebo/no treatment in risk of serious adverse events, withdrawal due to adverse events, or any adverse event … to 2.07), withdrawal due to adverse events (3 trials, n = 1875; RRs, 4.73 to 38.20), and any adverse event

186. Final Research Plan: Cardiovascular Disease Risk: Screening With Electrocardiography | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/cardiovascular-disease-risk-screening-with-electrocardiography
     July 14, 2016 - Share to Facebook Share to X Share to WhatsApp Share to Email Print Final Research Plan Cardiovascular Disease Risk: Screening With Electrocardiography July 14, 2016 Recommendations made by the USPSTF are independent of the U.S. government. …

187. Screening for Anxiety in Children and Adolescents: US Preventive Services Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/qWZxPBqpffTYVNvGYPkohz
     May 01, 2021 - Screening for Anxiety in Children and Adolescents: US Preventive Services Recommendation Statement Screening for Anxiety in Children and Adolescents US Preventive Services Task Force Recommendation Statement US Preventive Services Task Force Summary of Recommendations See the Summary of Recommendations figure. Imp…

188. Evidence Summary: Prediabetes and Type 2 Diabetes: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/screening-for-prediabetes-and-type-2-diabetes
     August 24, 2021 - with moderate or high strength of evidence (for benefit), using the pooled RRs and the control group event … all-cause mortality, cardiovascular-related mortality, and the occurrence of a first cardiovascular event … with placebo (liraglutide, sitagliptin, metformin, nateglinide, and rosiglitazone plus metformin); event

189. Archived: Peripheral Arterial Disease (PAD) and CVD in Adults: Risk Assessment with Ankle Brachial Index | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/peripheral-arterial-disease-pad-and-cvd-in-adults-risk-assessment-with-ankle-brachial-index-2013
     September 15, 2013 - Share to Facebook Share to X Share to WhatsApp Share to Email Print archived Final Recommendation Statement Peripheral Arterial Disease (PAD) and CVD in Adults: Risk Assessment with Ankle Brachial Index September 15, 2013 Recommendations ma…

190. Final Research Plan: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Falls and Fractures in Community-Dwelling Adults: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/vitamin-d-calcium-combined-supplementation-primary-prevention-falls-fractures-communitydwelling-adults
     April 06, 2023 - Share to Facebook Share to X Share to WhatsApp Share to Email Print in progress Final Research Plan Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Falls and Fractures in Community-Dwelling Adults: Preventive Medicatio…

191. Archived: Evidence Summary: Blood Pressure in Children and Adolescents (Hypertension): Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary16/blood-pressure-in-children-and-adolescents-hypertension-screening-october-2013
     February 15, 2013 - Adverse event data were often poorly reported, and most studies reported noncomparative data from open-label … Headache was the most common specific adverse event in most studies: rates ranged from 2% to 33% in children … In one study, a combination of bisoprolol and hydrochlorothiazide was associated with lower adverse event … in the incidence of specific adverse events, including headache (the most commonly reported adverse event … withdrawal study 12.2 (2.97) 422 screened; 302 randomized Olmesartan medoxomil Any adverse event

192. Final Research Plan: Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/menopausal-hormone-therapy-preventive-medication
     May 27, 2021 - for HT use such as history of breast cancer, coronary heart disease, a previous venous thromboembolic event

193. Screening for Hypertension in Children and Adolescents (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/Aqm6uW6_HrTRVJ-EVCVaRV
     March 01, 2013 - al­ though specific rates were not always reported.53,54,56–59,68–71 Two studies pooled adverse event … reported no active treatment and placebo arms, and significant difference between active adverse event … rates overall ere not well- treatments and placebo in adverse event reported in most studies. rates … one study, a combination of bisoprolol and hydrochlorothiazide was associated with lower adverse event … the incidence of specific adverse events, including headache (the most commonly reported adverse event

194. Final Evidence Summary: Depression and Suicide Risk in Children and Adolescents: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary27/screening-depression-suicide-risk-children-adolescents
     October 11, 2022 - Comparable intensity of therapy in study groups, coupled with low-event rates for some outcomes (such

195. Evidence Summary: Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/behavioral-counseling-and-pharmacotherapy-interventions-for-/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions
     September 21, 2015 - . 40 , 49 Nicotine replacement therapy was associated with an increased risk for any cardiovascular event … varenicline were superior to placebo for smoking cessation and that none seemed to have an adverse event … AE = adverse event; CV = cardiovascular; ENDS = electronic nicotine delivery system; KQ = key question … AE = adverse event; KQ = key question; NA = not applicable; NRT = nicotine replacement therapy; SR = … 24, or 52 wk No difference in frequency of AEs among study groups at each time point AE = adverse event

196. Archived: Evidence Summary: Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/behavioral-counseling-and-pharmacotherapy-interventions-for-/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions-september-2015
     September 21, 2015 - 40 , 49 Nicotine replacement therapy was associated with an increased risk for any cardiovascular event … varenicline were superior to placebo for smoking cessation and that none seemed to have an adverse event … AE = adverse event; CV = cardiovascular; ENDS = electronic nicotine delivery system; KQ = key question … AE = adverse event; KQ = key question; NA = not applicable; NRT = nicotine replacement therapy; SR = … 52 wk No difference in frequency of AEs among study groups at each time point AE = adverse event

197. Update on the Methods of the U.S. Preventive Services Task Force: Estimating Certainty and Magnitude of Net Benefit (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/4y3P9DxovKMEjNmVd2mrPp
     December 01, 2007 - www.annals.org 18 December 2007 Annals of Internal Medicine Volume 147 • Number 12 873 vent 1 adverse health event … number of people who would need to be screened for some defined period to prevent 1 adverse health event … number of people who would need to be treated or screened for a defined time to cause 1 adverse health event

198. Final Recommendation Statement: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/breast-cancer-medications-for-risk-reduction
     September 03, 2019 - Younger women with no risk factors for cardiovascular disease are less likely to have a cardiovascular event … Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women … 5) ND ND Harms: Events Increased (95% CI) a Vascular    Venous thromboembolic event

199. Draft Research Plan: Chronic Kidney Disease: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/draft-research-plan/chronic-kidney-disease-screening
     January 19, 2023 - Share to Facebook Share to X Share to WhatsApp Share to Email Print in progress Draft Research Plan Chronic Kidney Disease: Screening January 19, 2023 Recommendations made by the USPSTF are independent of the U.S. government. They should not …

200. Screening for HIV: Systematic Review to Update the 2005 USPSTF Recommendation (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/dvcAbDQWejyK38oxF8qgka
     November 01, 2012 - ART (adjusted RR, 1.3 per year of exposure [CI, 1.1 to 1.4 per year of exposure]), although absolute event … sex, HIV transmission group, race, calendar year, cohort, smoking, family history of CVD, previous CV event … lamivudine, abacavir Age, sex, risk group, race, cohort, BMI, family history of CVD, smoking, previous CV event … Age, sex, cohort, HIV transmission group, race, age, BMI, family history of CVD, smoking, previous CV event